60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
DUBLIN - Bank of America Corporation has disclosed a 2.98% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Today.
The disclosure, made under Irish Takeover Panel rules, reveals Bank of America holds interests in 2,898,683 ordinary shares, representing approximately 2.98% of Avadel's securities. This includes 2,478,603 shares owned or controlled directly and 420,080 shares through cash-settled derivatives.
The filing also shows Bank of America maintains short positions in 1,967,314 shares, equivalent to about 2.02% of the company. These short positions consist of 652,378 relevant securities owned or controlled and 1,314,936 cash-settled derivatives.
The disclosure details multiple transactions conducted on October 27, including purchases of Avadel shares at prices ranging from $18.54 to $18.59 per share, and sales between $18.54 and $18.58 per share.
The regulatory filing was submitted in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
Avadel Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medications for central nervous system disorders.
The information was released in a Form 8.3 filing through the Regulatory Information Service of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.